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Abstract
U.S. EPA’s integrated risk information system (IRIS) assessment of 2-butoxyethanol (EGBE) indicates that the human car-
cinogenic potential of EGBE cannot be determined at this time, but that “suggestive evidence” for cancer exists from laboratory
animal studies (hemangiosarcoma of the liver in male mice and forestomach squamous cell papilloma or carcinoma in female
mice [National Toxicology Program (NTP), 2000a. Toxicology and carcinogenesis studies of 2-butoxyethanol (CAS no. 111-
76-2) in F344/N rats and B6C3F1 mice (inhalation studies). National Toxicology Program Technical Report Series No. 484.
U.S. Department of Health and Human Services, National Institutes of Health, Washington, DC]). Since the last EGBE IRIS
assessment, a number of studies have provided evidence that the carcinogenic effects observed in mice are nonlinear in their
mode of action and may be dependent on threshold events such as EGBE-induced hemolytic effects. EPA is in the process of
considering several questions relating to this issue. First, can a plausible mode of action be determined for the two types of tumors
observed in mice? Second, are the mechanisms involved applicable to humans? If so, should the mode of action be considered to
result in a linear or nonlinear dose–response? These questions will be addressed within the context of the agency’s new cancer
guidelines and with regard to how the answers might affect a revised IRIS assessment for EGBE.
© 2004 Elsevier Ireland Ltd. All rights reserved.
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1. Background
Ethylene glycol butyl ether (EGBE; 2-
butoxyethanol) is a chemical solvent widely used in
formulating cleaning products and protective coatings.
It has been studied extensively in oral, dermal, and
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inhalation toxicological studies of several species
(U.S. EPA, 1999a); and hemolysis is consistently
observed as the primary effect of EGBE exposure. The
2-butoxyacetic acid (BAA) metabolite of EGBE has
been shown to be the causative agent in this hemolysis.
In vitro studies have shown that the red blood cells
of humans are less sensitive to the hemolytic effects
of EGBE/BAA than are those of typical laboratory
species (Ghanayem, 1989; Udden, 2002). In addition,
0378-4274/$ – see front matter © 2004 Elsevier Ireland Ltd. All rights reserved.
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no hemolysis has been observed in controlled labora-
tory acute inhalation exposures of human volunteers
to up to 195 ppm EGBE (Carpenter et al., 1956).
Effects in humans from long-term exposure to EGBE
have not been studied (U.S. EPA, 1999a). However,
long-term exposure studies of rats and mice have
reported both hemolytic and carcinogenic effects
(NTP, 2000a), raising concern that EGBE might be a
human carcinogen.
Based on the available data and using the 1996 pro-
posed guidelines for carcinogen risk assessment (U.S.
EPA, 1996), EPA reported in its 1999 IRIS assessment
(U.S. EPA, 1999a) that the human carcinogenicity of
EGBE cannot be determined at this time, but that sug-
gestive evidence (i.e., slight increases in liver heman-
giosarcomas in male mice and forestomach tumors in
female mice) exists from rodent studies. Under the ex-
isting EPA guidelines (U.S. EPA, 1986), EGBE was
judged to be a “possible human carcinogen”. A quan-
titative assessment of EGBE’s cancer potency was not
derived due to uncertainties associated with the human
relevance of the mode of action for the formation of
the tumors that were observed in laboratory animals
following EGBE exposure.
Since the completion of the EGBE IRIS assess-
ment (U.S. EPA, 1999a), several studies have been
performed to investigate possible carcinogenic mecha-
nisms for the development of liver hemangiosarcomas
in male mice (Kamendulis et al., 1999; Siesky et al.,
2001, 2002; Park et al., 2002a,b) and forestomach tu-
mors in female mice (Bennett, 2000; Poet et al., 2003;
Corley et al., 1999; Green, 2000; Poet et al., 2002) fol-
lowing exposure to EGBE. This paper discusses the
mode of action for and human relevance of carcino-
genic effects observed in mice following EGBE expo-
sure in light of these new studies, with particular focus
on liver effects observed in male mice because of their
higher potential relevance to humans.
2. Mode of action for tumors observed in
EGBE-exposed animals
Although results of available in vitro genotoxic-
ity assays have been somewhat mixed, recent reviews
(Commonwealth of Australia, 1996; Elliot and Ashby,
1997; U.S. EPA, 1999a; NTP, 2000a) agree that EGBE
is not likely to be genotoxic in vivo. Based on chemi-
cal structure, EGBE itself does not resemble any known
chemical carcinogens and is not expected to have elec-
trophilic or DNA reactive activity. However, as is exten-
sively discussed in the agency’s draft cancer guidelines
(U.S. EPA, 1999b), chemicals can have a range of key
influences as initiators or promoters of the complex car-
cinogenic process. With this in mind, EGBE’s role in
the formation of female mouse forestomach and male
mouse liver tumors observed following 2 years of in-
halation exposure (NTP, 2000a) were assessed. These
evaluations were done using the framework for evalu-
ating mode of action that is outlined in the U.S. EPA
(1999b) draft cancer guidelines.
2.1. Forestomach papillomas and carcinoma
observed in female mice
2.1.1. Background
Table 1 summarizes the data for key tumor types that
have been observed in female mice (NTP, 2000a). At
the 250 ppm exposure level, the 10% incidence of squa-
mous papilloma and 12% incidence of squamous cell
papilloma or carcinoma (combined) were significantly
increased over study controls (0% incidence). The his-
torical range of forestomach tumors in control mice
from NTP inhalation carcinogenicity studies averaged
0.3% and ranged from 0% to 2% for carcinomas and
averaged 1.6% and ranged from 0% to 6% for papillo-
mas (Haseman et al., 1998). NTP (2000a,b) reports that
8% is the highest incidence of forestomach neoplasms
that has been observed in any contemporary historical
control group. NTP (2000a) did not observe significant
increases in forestomach papillomas and carcinomas at
other exposure levels in female mice, nor at any expo-
sure level in male mice or either sex of rats.
2.1.2. Dosimetry
In addition to EGBE, forestomach hyperplasia in
male and female mice has been associated with va-
por inhalation exposure to acetonitrile (NTP, 1996),
1,3-butadiene (NTP, 1993a) and chloroprene (NTP,
1998a,b). Given that the rodent forestomach is known
to be poorly vascularized and that the cells of the epithe-
lium, especially the more superficial squamous cells,
are separated from capillaries by substantial diffusion
distances (Bueld and Netter, 1993), it seems more likely
that these compounds or their metabolites are delivered
to the forestomach by ingestion rather than system-
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Table 1
Key tumors observed in female mice (NTP, 2000a)
Control 62.5 ppm 125 ppm 250 ppm
Squamous cell papilloma-forestomach 0/50 1/50 2/50 5/50
Overall rate (%) 0 2 4 10
Rate adjusted for intercurrent mortality (%)a 0 2.4 4.8 11.2
First incidence (days) NA 731 731 582
Squamous cell papilloma or carcinoma-forestomach 0/50 1/50 2/50 6/50
Overall rate (%) 0 2 4 12
Rate adjusted for intercurrent mortality (%) 0 2.4 4.8 13.4
First incidence (days) NA 731 731 582
a Poly-3 test estimate taken from NTP (2000a) technical report series 484.
ically. In the case of EGBE, it has been shown that
upon iv administration, EGBE metabolites can rapidly
accumulate in salivary secretions which are swallowed
(Bennett, 2000) and that ip injection causes forestom-
ach lesions similar to those observed in gavage and
inhalation studies (Corley, 1999). Corley et al. (1999)
have suggested that the minimal lesions observed fol-
lowing sc administration of similar doses is an indica-
tion of the importance of first-pass liver metabolism. If
first-pass metabolism is important, however, an expla-
nation must be provided for why forestomach hyperpla-
sia was not reported in the subchronic drinking water
study at comparable mg/kg/day doses (NTP, 1993b). It
is possible that the formation of lesions requires persis-
tent and high EGBE metabolite (BAA) concentrations
in the forestomach that are attainable following gavage
(Ghanayem et al., 1987a), inhalation (Green, 2000),
and ip exposures (Poet et al., 2002), but are not attain-
able from drinking water exposure.
Because systemic circulation alone is not likely to
be responsible for the occurrence of forestomach le-
sions in these inhalation studies, other sources of in-
gested EGBE or EGBE metabolites must be consid-
ered. Researchers have established the following: (a) a
small amount (9–10 mg/kg) of neat EGBE was likely
available for oral consumption via daily grooming fol-
lowing the NTP inhalation exposures (Corley et al.,
1999; Green, 2000); (b) the forestomachs of ro-
dents are known to sequester EGBE for an extended
period of time after gavage exposures (Ghanayem
et al., 1987a); (c) direct, neat exposure to EGBE, with-
out first-pass liver metabolism, can cause forestom-
ach lesions similar to those observed by the NTP
(2000a,b) following inhalation exposure (Corley et al.,
1999); (d) EGBE causes cytotoxicity through its 2-
BAA metabolite (Udden, 2000); (e) concentration is
a more critical factor than duration with respect to
BAA’s ability to cause cell lysis (U.S. EPA, 1999c).1
These findings suggest that active irritant metabolites
of EGBE may be produced locally in the forestomach.
It is also possible that tissues of the upper respiratory
tract produce metabolites of EGBE,2 which are trans-
ferred to secretions and swallowed. It is more plausible
that some combination of grooming followed by local
metabolism, and the swallowing of metabolized respi-
ratory tract secretions, followed by chronic irritation,
is responsible for the formation of these lesions.
2.1.3. Pathology
The high concentrations of EGBE and its BAA
metabolite sequestered in the forestomach through pro-
longed exposure are assumed to be the cause of chronic
irritation and the more serious damage observed in the
forestomach lining of female mice. Incidences of ulcers
consisting of a lesion in the forestomach wall that pene-
trated the full thickness of the forestomach epithelium
were significantly increased in all exposed groups of
females. NTP (2000a) suggests that EGBE exposure
caused inflammatory and hyperplastic effects in the
forestomach and that “the neoplasia [papillomas and
one carcinoma] was associated with a continuation of
the injury/degeneration process”.
1 This is why Cmax and not AUC was used as an internal dose met-
ric for animal to human adjustments performed in the establishment
of the inhalation RfC.
2 The upper respiratory tract of rodents, including the olfactory
epithelium, has been found to contain significant metabolic capacity
with respect to acrylates and other compounds (Mattes and Mattes,
1992; Green, 1996; Bogdanffy et al., 1987).
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No clear explanation has been presented in the litera-
ture for the lack of sensitivity of male mice to forestom-
ach neoplasms by the inhalation exposure route (Can-
tox Environmental Inc., 2000). However, female mice
of the NTP (2000a) study were clearly more susceptible
to inflammation and hyperplasia than males at similar
exposure levels; and it is likely that these tumors oc-
curred via indirect mechanisms involving chronic tis-
sue injury. Forestomach effects, particularly tumor ob-
servations in females, were preceded or accompanied
by marked signs of irritation, including hyperplasia and
ulceration. The female mice of this 2-year inhalation
study experienced hyperplasia of the epithelium in the
forestomach at all exposure levels (54% at 62.5 ppm,
86% at 125 ppm, and 88% at 250 ppm), as did female
mice in the 14-week inhalation study (NTP, 2000a). No
similar evidence of hyperplasia was noted in mice or
rats in an earlier 13-week drinking water study (NTP,
1993a,b,c).
2.2. Liver hemangiosarcomas in male mice
2.2.1. Background
Table 2 summarizes the data for key tumor types ob-
served in male mice exposed to EGBE by inhalation in
studies conducted by NTP (2000a). Particular focus has
been placed on hemangiosarcomas of the liver as this is
the only organ site with an increased incidence of this
tumor type. However, combination of this cardiovas-
cular system (vascular endothelium) tumor type across
organ systems is also considered potentially relevant
for quantifying cancer risk. The combined incidence
of hemangiomas and hemangiosarcomas is considered
potentially relevant although the suggestion that he-
mangiomas represent a first stage in the development
of hemangiosarcomas is not universally accepted, even
for chemicals that are known to act by a direct genotoxic
mechanism (McConnell et al., 1986). Establishment of
the mode of action for the development of these tumors
in mice would be important for any quantitative assess-
ment of potency (i.e., selecting a linear or nonlinear
dose–response modeling method) and any qualitative
determination of human relevance.
3. Postulated mode of action
In the EGBE IRIS assessment (U.S. EPA, 1999a),
EPA determined that the information available did not
allow for a definitive statement regarding the mode
of action for the increase in the incidence of heman-
giosarcomas in the livers of male mice. Since that
time, considerable research has been completed in this
area, and several scientists have postulated a hemolysis-
mediated mode of action for the formation of these tu-
mors (Klaunig et al., 1998; Kamendulis et al., 1999;
Xue et al., 1999; Siesky et al., 2001; Foster, 2000;
Boatman, 2000; Park et al., 2002a,b; Klaunig, 2002).
This section will examine these new research findings
and proposals in light of the agency’s recently pub-
lished draft cancer guidelines (U.S. EPA, 1999b).
In general, the current draft of the guidelines (U.S.
EPA, 1999b) requires discussion of the proposed mode
of action, the strength of its supporting database,
Table 2
Key tumors observed in male mice (NTP, 2000a)
Control 62.5 ppm 125 ppm 250 ppm
Hemangiosarcomas—all organs 1/50 1/50 2/50 5/50
Overall rate (%) 2 2 4 10
Rate adjusted for intercurrent mortality (%)a 2.2 2.1 5.0 12.4
First incidence (days) 729 670 704 454
Hemangiosarcomas—liver only 0/50 1/50 2/49 4/49
Overall rate (%) 0 2 4 8
Rate adjusted for intercurrent mortality (%) 0 2.1 5.0 10
First incidence (days) NA 670 704 454
Hemangiosarcomas/hemangiomas—all organs 1/50 1/50 4/50 5/50
Overall rate (%) 2 2 8 10
Rate adjusted for intercurrent mortality (%) 2.2 2.1 10 12.4
First incidence (days) NA 670 704 454
a Poly-3 test estimate taken from NTP (2000a) technical report series 484.
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Fig. 1. Framework of EPA guidelines for risk assessment [numbers
in the boxes refer to sections in the draft cancer guidelines (U.S. EPA,
1999b)].
whether it is believed to be operative in humans, and
whether any human subpopulation is apt to “qualita-
tively respond to the mode of action differently than the
general population”. The framework for this approach
is illustrated in Fig. 1 and is applied here to assess the
mode of action for EGBE-induced liver hemangiosar-
comas in male mice and its relevance to humans. The
following is a six-step summary of the mode of action
that has been proposed.
1. EGBE is metabolized via alcohol dehydrogenase to
2-butoxyacetaldehyde which is oxidized via alde-
hyde dehydrogenase to 2-butoxyacetic acid (BAA).
2. BAA causes hemolysis of red blood cells.
3. Hemosiderin derived from the excess hemoglobin is
taken up by and stored in phagocytic (e.g., Kupffer)
cells of the spleen and liver.
4. Oxidative damage and increased synthesis of en-
dothelial DNA are initiated by one or more of the
following events:
- Generation of reactive oxygen species (ROS)
from iron within Kupffer cells (Siesky et al., 2002;
Park et al., 2002a,b).
- Generation of ROS from excess iron that directly
enters sinusoidal endothelial cells (Foster, 2000).3
- Activation of Kupffer cells to produce cy-
tokines/growth factors which suppress apopto-
sis and promote cell proliferation (Siesky et al.,
2002).
5. Chronically increased DNA synthesis and damage
leads to endothelial DNA mutations.
6. Potentiation and promotion of neoplastic cell pop-
ulations results from accumulation of multiple en-
dothelial DNA mutations.
3.1. Strength, consistency, and specificity of
association of tumor response with key events
This hypothesized mode of action would suggest
that the pathology of hemangiosarcoma development
from EGBE exposure is nonlinear and dependent upon
the level of hemolysis, the amount of iron buildup
within the target cell population, and the repair capac-
ity of that cell population. The first four key events
listed above are fairly well described and documented
in the EGBE literature. Steps 1 and 2, the metabolism
of EGBE to BAA and the association of BAA with
hemolytic effects has been clearly established in mul-
tiple in vivo and in vitro tests involving both sexes of
several species, including rats and mice (U.S. EPA,
1999a).
Step 3 has been verified through the observation of
hemosiderin (iron) within Kupffer cells and hepato-
cytes following prolonged breakdown of the red blood
cells in both sexes of rats and mice exposed to EGBE
(NTP, 2000a; Ghanayem and Sullivan, 1993;
Ghanayem et al., 1987b,c; Krasavage, 1986;
Kamendulis et al., 1999; Siesky et al., 2002). A
possible indication of the importance of hemolysis
to tumor formation is given by the fact that splenic
hematopoietic cell proliferation in the mice with liver
hemangiosarcomas was reported to be more severe
(average severity grade of 3.2 for all dose groups)
3 It is possible that a continued cycle of hemolysis and hemoglobin
release can eventually overwhelm normal phagocytic mechanisms,
causing iron to appear within cells that normally would not contain
significant amounts of hemosiderin, such as the hepatocytes and si-
nusoidal endothelial cells. However, the necessity and extent of such
buildup are not clear (see later discussion of“the relation between
Kupffer cell pigmentation and the sinusoidal endothelial cells”).
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than in mice that did not develop hemangiosarcomas
(average severity grade of 2.3).
A recent gavage study (Siesky et al., 2002) of rats
and mice subchronically exposed to EGBE provides
support for step 4 of the proposed mechanism, the
induction of oxidative damage and increased DNA
synthesis within endothelial cells. However, some
uncertainty remains regarding this step in the proposed
mechanism. These and other investigators
(Kamendulis et al., 1999; Park et al., 2002a)
have indeed demonstrated the observed hepatic
oxidative stress is more likely to result from EGBE-
induced hemolysis and the subsequent increase in
iron deposition rather than through a compound or
metabolite-specific mechanism. However, Siesky
et al. (2002) looked for but did not observe iron
within endothelial cells, and the observed indicators
of oxidative damage (increased OH8dG and mal-
ondialdehyde levels) were only recorded for total
liver. Thus, they did not provide evidence for a direct
link between iron induced endothelial cell DNA
damage and the observed increase in endothelial cell
DNA synthesis. This may or may not be important.
Siesky et al. (2002) and Rose et al. (1997, 1999)
have suggested that increased endothelial cell DNA
synthesis and oxidative damage can occur without
direct iron involvement through indirect Kupffer cell
activation leading to the release of cytokines and
growth regulatory molecules, which contribute to the
induction of endothelial DNA synthesis and damage.
Given the apparent predisposition of male mouse
endothelial cells to carcinogenic transformation,
this may be enough to trigger mutations and tumor
formation. Yet, due to the large amount of hemosiderin
that was observed in Kupffer cells and the relative
insensitivity of the Perl staining tests employed, it is
also possible that some significant amount of iron can
penetrate and have a more direct impact on endothelial
cells (Ghio, 2002).
The last two key events of the proposed mode of
action suggest that the extent and duration of oxida-
tive damage and increased DNA synthesis within en-
dothelial cells are sufficient to lead to fixed mutations
and the potentiation and promotion of neoplastic cell
populations. These proposed steps are not so well doc-
umented, but are consistent with evidence from other
studies of chemicals that cause hemosiderin buildup
in male mice. Table 3 presents the liver hemangiosar-
comas incidence for all chemicals identified in NTP
studies4 as causing hemosiderin pigmentation of the
Kupffer cells following chronic exposure.5 None of the
six chemicals found to cause Kupffer cell hemosiderin
pigmentation in male or female rats following chronic
exposure (any route) caused a statistically significant
increase in liver hemangiosarcomas. Similarly, none
of the seven chemicals found to cause hemosiderin
buildup in Kupffer cells of female mice6 caused an in-
crease in liver hemangiosarcomas. In contrast, chronic
exposure to four of the seven chemicals causing Kupf-
fer cell hemosiderin pigmentation in male mice caused
significant increases in the incidence of liver heman-
giosarcomas.
Male mouse sensitivity over rats and female mice
may be explained by an increased sensitivity to ox-
idative stress (Kamendulis et al., 1999; Siesky et al.,
2001) and predisposed endothelial cells. The latter is
indicated by the higher historical control incidence of
hemangiosarcomas in male mice (see discussion be-
low of male versus female historical rates). The fact
that mice, but not rats, experience early increases in
endothelial cell DNA synthesis (Siesky et al., 2002)
and a sustained hemolytic response (see discussion of
temporal relationships below), would also be consistent
with the apparent mouse liver specificity for this tumor.
3.2. Temporal association
Key steps in the proposed mode of action
hemolysis—hemosiderin buildup and oxidative
damage—have all been observed in subchronic or
shorter duration rat and mouse studies (NTP, 2000a;
Kamendulis et al., 1999; Siesky et al., 2002), well in
advance of tumor formation. Increased endothelial
4 Data for Table 3 were obtained via a search of NTP’s
post-PWG TDMS database (http://ntp-apps.niehs.nih.gov/postpwg/
webapp.open.cfm).
5 Chemicals were not included if they caused pigmentation that
was not believed to be hemosiderin, such as bile or porphyrin pig-
mentation, and was not observed in the Kupffer cells.
6 Pentachlorophenol (Dowicide and Technical grade) caused a sta-
tistically significant increase in liver hemangiosarcomas, but the liver
pigmentation observed was not identified as hemosiderin and was not
in the Kupffer cells. Since pentachlorophenol is genotoxic and causes
precursor lesions of the liver similar to those observed following ex-
posure to vinyl chloride, it is likely that it is acting by a different
mode of action than that which is proposed for EGBE.
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Table 3
Incidence of liver hemangiosarcomas in NTP chemicals causing increased hemosiderin in Kupffer cells
Chemical—NTP TR# Hemosiderin (chronic study) 14-Week study Hemangiosarcoma Route
Male rats (F344)
2-Butoxyethanol (EGBE)—TR-484 23/50, 30/50, 34/50, 42/50 Yes 0/50, 0/50, 1/50, 0/50 Inh.
Butyl benzyl phthalate—TR-458 2/60, 1/60, 6/60, 6/60 No None reported Feed
p-Chloroaniline hydrochloride—TR-351 1/49, 0/50, 0/50, 26/50 No Not reported Gavage
o-Nitroanisole—TR-416 0/20, 1/20, 18/20 No None reported Feed
Pyridine—TR-470 4/50, 11/50, 20/50, 25/50 No None reported Water
Female rats (F344)
2-Butoxyethanol (EGBE)—TR-484 15/50, 19/50, 36/50, 47/50 Yes 0/50, 0/50, 0/50, 0/50 Inh.
Butyl benzyl phthalate—TR-458 4/60, 1/60, 6/60, 10/60 No None reported Feed
CI pigment red 3—TR-407 0/50, 3/50, 14/50, 41/50 No None reported Feed
o-Nitroanisole—TR-416 8/20, 2/20, 20/20 No None reported Feed
Pyridine—TR-470 6/50, 2/50, 6/50, 17/50 No None reported Water
Male mice (B6C3F1)
2-Butoxyethanol (EGBE) 0/50, 0/50, 8/50, 30/50 Yes 0/50, 1/50, 2/50, 4/50 Inh.
p-Chloroaniline hydrochloride—TR-351 0/50, 0/49, 0/50, 50/50 Yes 2/50, 2/49, 1/50, 6/50 Gavage
p-Nitroaniline—TR-418 1/50, 1/50, 8/50, 50/50 Yes 0/50, 1/50, 2/50, 4/50 Gavage
Pentachloroanisole—TR-414 1/50, 50/50, 50/50a Yes 2/50, 8/50, 10/50 Gavage
CI pigment red 3—TR-407 0/50, 5/50, 30/50, 41/50 No 0/50, 1/50, 1/50, 0/50 Feed
2,4-Diaminophenol dihydrochloride—TR-401 0/50, 44/50, 47/50 No 1/50, 0/50, 1/50 Gavage
o-Nitroanisole—TR-416 0/50, 0/50, 3/50, 16/50 No 2/50, 2/50, 1/50, 0/50 Feed
Female mice (B6C3F1)
2-Butoxyethanol (EGBE)—TR-484 0/50, 5/50, 25/50, 44/50 Yes 0/50, 0/50, 1/50, 0/50 Inh.
p-Chloroaniline hydrochloride—TR-351 0/50, 0/50, 1/50, 46/50 Yes 1/50, 0/50, 0/50, 1/50 Gavage
CI pigment red 3—TR-407 2/50, 1/50, 1/50, 29/50 No 0/50, 1/50, 0/50, 0/50 Feed
2,4-Diaminophenol dihydrochloride—TR-401 0/50, 31/50, 50/50 No 0/50, 0/50, 0/50 Gavage
Methyleugenol—TR-491 0/50, 11/50, 24/50, 19/50b No 0/50, 1/50, 0/50, 0/50 Gavage
p-Nitroaniline—TR-418 1/50, 1/50, 4/50, 39/50 No 1/50, 1/50, 0/50, 0/50 Gavage
Pentachloroanisole—TR-414 0/50, 37/50, 48/501 Yes 0/50, 0/50, 1/50 Gavage
a Authors reported (NTP, 1993c) Kupffer cells with yellow-brown granules of undetermined identity. “Appropriate staining procedures” did
not reveal iron, bile or PAS-positive materials in these granules. The authors suggested that they may consist of one or more porphyrins because
cellular porphyrins are known to be produced from exposure to other chlorinated hydrocarbons. However, the possibility that the pigmentation
may have consisted of hemosiderin “was not entirely eliminated”.
b Pigment identified as hemosiderin, but not explicitly reported in Kupffer Cells (NTP, 2000c).
cell DNA synthesis was observed at exposure days 7
and 14 in mice, but not rats. This may be an indication
of the need for very early lifestage endothelial cell
damage.
The importance of early lifestage and sustained
endothelial cell damage may also be given by the
fact that of the seven chemicals found to increase
hemosiderin levels in male mice (Table 3), only the
four chemicals that did so within 14 weeks (EGBE, p-
chloroaniline, p-nitroaniline, and pentachloroanisole7)
7 It is not clear that the “yellow-brown granules” found in Kupf-
fer cells of rats and mice exposed to pentachloroanisole contained
hemosiderin (NTP, 1993c). “Appropriate staining procedures” did
not reveal iron, and there was no evidence of hemolytic activity. The
were shown to induce hemangiosarcomas. In studies
of the other three chemicals, hemosiderin buildup was
not observed until the end of the 2-year study. Early
buildup of hemosiderin (combined with early increases
in endothelial cell DNA synthesis) would result in a
longer exposure of cells to oxidative damage via iron-
generated radicals (step 4) which would be consistent
with a mechanism involving a continuing cycle of dam-
age and repair and accumulation of DNA mutations
(steps 5 and 6). Thus, it is possible that the three chem-
icals did not induce liver hemangiosarcomas because of
authors suggested that they may consist of one or more porphyrins,
but none were identified. Thus, the possibility that the pigmentation
consisted of hemosiderin “was not entirely eliminated”.
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temporal differences in their initiation of hemosiderin
buildup.
A possible explanation for the lack of heman-
giosarcomas in rats may be that mice experience a
more sustained hemolytic response to EGBE than rats.
Mice experienced an increase in liver and splenic
hematopoietic cell proliferation throughout the 2-year
NTP (2000a) study while rats did not show evidence
of a sustained hemolytic response,8 and do not develop
hemangiosarcomas.
3.3. Dose–response relationships
As can be seen from the EGBE-specific data in
Table 3, the liver hemangiosarcoma response in the four
male mouse studies for which subchronic hemosiderin
buildup was observed appears to be dose-related. End-
points describing alleged precursor effects, splenic
hematopoietic cell proliferation, and liver hemosiderin
accumulation are coincident and dose-related (U.S.
EPA, 1999a).
3.4. Biological plausibility and coherence of the
database
Oxidative damage is increasingly recognized as
playing an important role in the pathogenesis of sev-
eral diseases, including carcinogenesis and cardio-
vascular disease (Lesgards et al., 2002). In support
of the proposed hypothesis, increased reactive oxida-
tive stress is known to accompany large amounts of
iron released during hemolysis (Ziouzenkova et al.,
1999). If EGBE causes oxidative stress by this mode
of action one would expect to observe the production
of protein and DNA damage following EGBE expo-
sure, some of which will occur via the production of
adducts of OH8dG (Yamaguchi et al., 1996; Wang
et al., 1995; Houglum et al., 1997). This was verified by
both Kamendulis et al. (1999) and Siesky et al. (2001),
who measured a dose-dependent increase in levels of
OH8dG and MDA and a decrease in Vitamin E levels in
8 Though rats are initially more sensitive to hemolysis than mice
and were used to derive the EPA RfC for EGBE, they tend to com-
pensate for the effects of EGBE after a few months. This increased
tolerance is documented in the IRIS file for EGBE and is evidenced
by a lack of induction of splenic hematopoiesis at the end of the
2-year NTP (2000a) study.
the livers of mice acutely and subchronically exposed
to EGBE.
Liver hemangiosarcomas develop from the endothe-
lial cell component of the vascular sinusoidal cells of
the liver (Frith and Ward, 1979). The fact that iron
(hemosiderin), which is known to accumulate in cells
of rodent livers following EGBE exposure, can pro-
duce hydroxyl radicals in combination with oxidative
by-products via the Fenton reaction (Kamendulis et al.,
1999) has led several scientists (Xue et al., 1999; Siesky
et al., 2001; Foster, 2000; Boatman, 2000; Kamendulis
et al., 1999; Bachowski et al., 1997; Klaunig et al.,
1995) to suggest that male mouse liver hemangiosarco-
mas result from increased oxygen radical damage and
an associated increase in endothelial cell DNA synthe-
sis caused by excess iron from hemolysis. The dam-
aging effects of iron to liver sinusoidal cells in mice
exposed to a combination of lindane and iron (Junge
et al., 2001) lends support to this hypothesis. Addi-
tional support for this hypothesis is found in the fact
that endothelial cells do appear to be more susceptible
than other cells (e.g., hepatocytes or Kupffer cells) to
oxidative stress (DeLeve, 1998; Spolarics, 1999).
While largely supported by recent laboratory re-
search, several questions remain concerning the pos-
tulated mode of action. The questions outlined below
may be resolvable through further research. However,
they may indicate, as NTP (2000a) suggests, that the ac-
cumulation of hemosiderin and related oxidative stress
alone are not the sole cause of liver neoplasms in male
mice:
- Is the severity and incidence of observed Kupffer cell
pigmentation at terminal sacrifice sufficient to sug-
gest that oxidative stress from hemosiderin buildup
in these cells is solely responsible for the increased
incidence of liver hemangiosarcoma in the male
mouse?NTP (2000a) has suggested that hemosiderin
buildup is not related to the formation of liver heman-
giosarcomas because Kupffer cell pigmentation was
only of minimal severity and only observed in three
of the four high-dose male mice that developed this
tumor. However, given the apparent susceptibility
of male mouse endothelial cells, it is reasonable to
hypothesize that the reported minimal pigmentation
observed over such a large percentage of high-dose
animals (61% in the 250 ppm exposure group versus
0% in controls) could have caused the marginal
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increase in hemangiosarcomas reported for this dose
group (8% versus 0% in controls, with a 2.5% mean
historical background rate). Additionally, the fact
that Kupffer cell pigmentation was not reported for
one of the four mice with liver hemangiosarcomas
does not preclude the proposed mechanism because
(a) the Perls Prussian blue stain for iron performed
to determine the presence of hemosiderin is not a
particularly sensitive test (Ghio, 2002), and (b) the
observation of a liver hemangiosarcoma in 1/50
without hemosiderin buildup is not inconsistent with
the rate of incidence in historical controls, reported
to be 0–6% (mean of 2.5%) over all NTP studies of
male mice (NTP, 2000b).
- What is the relation between Kupffer cell pigmen-
tation and the sinusoidal endothelial cells, which
demonstrate no pigmentation and from which the
hemangiosarcomas arise? As discussed earlier, pro-
posed mechanisms for DNA damage and increased
synthesis do not necessarily involve the presence
of iron within the endothelial cells. However, the
observation of hemosiderin in the Kupffer cells
through rather insensitive staining methods suggests
that excess iron would be available to other, proximal
cells such as the sinusoidal endothelial cells.
- If hemosiderin buildup in Kupffer cells is impor-
tant for the development of EGBE-induced liver
hemangiosarcomas, why was the incidence of
this tumor not increased in the female mouse,
for which hemosiderin pigmentation was at least
as high as in the males? This observation is not
unique to EGBE. In fact, all four NTP chemicals
that induced early onset hemosiderin buildup in
conjunction with an increased incidence of this
tumor (EGBE, p-chloroaniline, p-nitroaniline, and
pentachloroanisole) exhibited this apparent male
specificity. Inherent differences between the antiox-
idant capacity of male versus female mice has been
offered (Foster, 2000) as a possible explanation for
the lack of a hepatic tumorigenic response in the lat-
ter. Though there is no direct evidence to support this
hypothesis, the historical incidence of hemangiosar-
comas does appear to be considerably higher in male
versus female mice. NIH/NTP has observed liver
hemangiosarcomas in 105 of the 4183 (2.51%) male
versus just 35 of the 4177 (0.84%) female historical
controls (NTP, 2000b; Klaunig, 2002). A more
definitive answer to this question could come from
additional research, perhaps involving measurement
of the relative capabilities of the antioxidant systems
of male and female mouse liver endothelial cells.
- Is the proposed relationship between the buildup of
hemosiderin in Kupffer cells and the development
of liver hemangiosarcomas supported by studies of
other chemicals? NTP (2000a) reported that they
did not find an association between hemosiderin
deposition in the liver and liver neoplasms (ade-
nomas, carcinomas, or hemangiosarcomas) in the
79 male and 103 female mice that had chemically
related liver neoplasms at the end of an NTP study.
However, a more focused review suggests that there
may be a relationship between hemosiderin buildup
in the Kupffer cells and liver hemangiosarcomas in
male mice. All of the four chemicals observed by
NTP to cause early onset (subchronic) hemosiderin
buildup in male mice induced an increase in the
incidence of liver hemangiosarcoma by the end of a
2-year NTP study (see Table 3).
- If hemosiderin deposition and increased hematopoi-
etic cell proliferation can lead to tumor formation,
why were no neoplasms noted in the spleen, where
these effects were also observed? Foster (2000)
suggests that cells of the spleen contain more
active compensatory systems to protect against
the harmful effects of iron buildup. This is not an
unreasonable hypothesis in that cells of the spleen
such as phagocytes do serve to rid the peripheral
circulation of damaged red blood cells and would
be expected to encounter high levels of hemoglobin
and hemosiderin in the process, thereby requiring
the need for greater protection against any harmful
effects from such buildup. The fact that phagocytic
cells of the spleen have a higher antioxidant capacity
than sinusoidal endothelial cells lends some support
to this hypothesis (DeLeve, 1998; Foster, 2000).
Thus, the proposed mode of action is not necessarily
inconsistent with the fact that hemosiderin buildup in
splenic cells did not lead to the type of tumor forma-
tion observed in the liver, particularly given the very
slight increase in liver tumor incidence observed.
3.5. Other possible modes of action for liver
hemangiosarcomas development in male mice
The most recognized mechanism for the develop-
ment of chemically induced liver hemangiosarcomas
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involves direct interaction with DNA (e.g., vinyl chlo-
ride). In vitro studies using rat and mouse hepatocytes
(Park et al., 2002a) and Syrian Hamster embryo (SHE)
cells (Park et al., 2002b) have also shown that EGBE
and a primary metabolite, 2-butoxyacetic acid, do not
directly induce oxidative damage, as measured by
increased OH8dG and MDA and decreased Vitamin E
levels at various exposure concentrations. In addition,
EGBE does not appear to demonstrate the same
pattern of effects as genotoxic compounds that cause
liver hemangiosarcomas (Foster, 2000; Telles et al.,
1979; Hong et al., 1980; Popper and Selikoff, 1981).
However, given that butoxyacetaldehyde, a short-lived
intermediate metabolite of EGBE, has been found to
be significantly more active than either butoxyethanol
or 2-butoxyacetic acid in mammalian cells in vitro
(Elias et al., 1996), the possibility for interaction
with DNA by metabolites of EGBE has not been
completely ruled out.
4. Relevance to humans
4.1. Forestomach papillomas and carcinoma
observed in female mice
It is clear that processes not relevant to humans
at least contributed to the formation of these tumors,
including consumption of bodily deposited EGBE,
deposition and metabolism of EGBE in the mouse
forestomach, and chronic irritation resulting from the
long-term storage of EGBE and its metabolites in
the forestomach. Incidences of ulcers consisting of
a lesion in the forestomach wall that penetrated the
full thickness of the forestomach epithelium were
significantly increased in all exposed groups of fe-
males; and NTP (2000a) suggests that EGBE exposure-
induced irritation caused inflammatory and hyperplas-
tic effects in the forestomach and that “the neopla-
sia [papillomas and one carcinoma] was associated
with a continuation of the injury/degeneration pro-
cess”. High concentrations of EGBE have been shown
to sequester in the forestomachs of mice following
gavage (Ghanayem et al., 1987a), inhalation (Green,
2000), and ip exposure (Poet et al., 2002). Due to
the questionable relevance of these processes and the
lack of a comparable organ in humans (an organ
which is both histologically and functionally similar
to the forestomach), the increased incidence of papil-
lomas and carcinomas in the forestomach of chron-
ically exposed high-dose female mice (NTP, 2000a)
are not considered appropriate for use in the estima-
tion of potential human cancer risk from EGBE expo-
sure.
4.2. Liver hemangiosarcomas in male mice
If male mouse liver hemangiosarcomas are indeed
secondary effects of hemolysis, like most other ef-
fects observed in rats and mice, they are not likely to
be relevant to humans. Iron overload in humans ei-
ther exposed to excess iron or genetically susceptible
due to defects in iron metabolism has been associ-
ated with the induction of liver tumors (Mandishona
et al., 1998; Stevens et al., 1994). However, humans
are not likely to experience significant iron buildup
from EGBE exposure because they are significantly
less sensitive to the hemolytic toxicity of EGBE than
rats and mice. Edmonson and Peters (1985) have sug-
gested that focal necrosis of the liver observed in male
rats following gavage administration of 250 and 500 mg
EGBE/kg (Ghanayem et al., 1987b) was not consis-
tent with typical anoxic centrilobular necrosis associ-
ated with anemia. However, no such effects have been
reported in other animal studies or humans. Though
effects in humans from chronic exposure to EGBE
have not been studied, no hemolysis has been ob-
served in controlled laboratory acute inhalation expo-
sures of human volunteers to up to 195 ppm EGBE
(Carpenter et al., 1956), and only reversible hemolytic
effects have been observed in humans acutely exposed
to high oral doses of 400–1500 mg/kg EGBE (U.S.
EPA, 1999a). Based on the results of in vitro test-
ing, blood concentrations of the hemolytically active
metabolite BAA must reach levels in human blood
in excess of 7.5 mM for even minimal prehemolytic
changes to occur. This is 15-fold higher than the
blood level at which comparable effects occur in rats
(Udden, 1995) and, according to the results of PBPK
modeling, higher than maximum blood concentrations
achievable from 6 h exposures of humans (whole body)
to saturated atmospheres of EGBE (Corley et al.,
1994).
In addition to the pharmacodynamic differences de-
scribed above, there are also pharmacokinetic differ-
ences in the rodent and human response to EGBE ex-
J.S. Gift / Toxicology Letters 156 (2005) 163–178 173
Fig. 2. Proposed Metabolic Scheme of EGBE in Rats and Humans (Adapted from Medinsky et al., 1990 and Corley et al., 1997).
posure (Fig. 2). The two main oxidative pathways of
EGBE metabolism observed in rats are alcohol dehy-
drogenase (ADH) andO-dealkylation by a cytochrome
P450 dealkylase (CYP 2E1) (Medinsky et al., 1990).
The former pathway, which involves the production of
the toxic metabolite BAA, is applicable to both rats
and humans. However, unlike rats, approximately two-
thirds of the BAA formed by humans is conjugated with
glutamine and glycine (Corley et al., 1997; Rettenmeier
et al., 1993). Thus, the glutamine and glycine detoxifi-
cation pathways may provide humans with some mea-
sure of added protection from the harmful effects of
BAA.
4.3. Relevance to susceptible subpopulations,
including children
4.3.1. Differences in susceptibility to hemolysis
The primary noncancer effect of EGBE is hemoly-
sis of red blood cells, which is caused by its primary
metabolite, BAA. The possibility exists that certain hu-
man subpopulations with red blood cell walls less resis-
tant to the lysis caused by BAA would be more sensi-
tive to EGBE. However, Udden (1994) has shown that
RBCs in normal and aged patients, and patients with
sickle-cell anemia and hereditary spherocytosis, are all
equally resistant to the hemolytic effects of BAA.
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4.3.2. Metabolic differences
Other potentially susceptible subpopulations in-
clude individuals with enhanced metabolism or de-
creased excretion of BAA. Older rats have been shown
to have a reduced ability to metabolize the toxic
metabolite BAA to CO2 and a diminished ability to
excrete BAA in the urine (Ghanayem et al., 1987c,
1990). However, the relevance of this finding to the
possible susceptibility of elderly humans is uncertain
due to the fact that humans may have conjugation path-
ways for the excretion of BAA (BAA-glutamine and
BAA-glycine) that are not available to the rat.
4.3.3. Genetic differences
Haufroid et al. (1997) conducted a human study on
workers exposed to EGBE to test the possible influence
of genetic polymorphism for CYP 2E1 on urinary BAA
excretion rate. One exposed individual exhibited a mu-
tant allele with increased cytochrome P450 oxidative
activity that coincided with a very low urinary BAA
excretion. However, the researchers did not measure
BAA conjugated to glutamine, an alternative pathway
for BAA excretion in humans. Further investigations on
the influence of genetic polymorphism for CYP 2E1 on
urinary BAA excretion rate are needed before any firm
conclusions can be drawn.
4.3.4. Gender differences
Slight gender differences have been noted in rodent
(Carpenter et al., 1956; Dodd et al., 1983; NTP, 1993b,
2000a), rabbit (Tyler, 1984), dog, monkey, and human
studies (Carpenter et al., 1956), with females being con-
sistently more susceptible to the primary hemolytic ef-
fects of EGBE. A number of secondary effects resulting
from the hemolytic toxicity of EGBE, such as effects
on the rat liver, kidneys, spleen, and bone marrow and,
to a lesser extent, the thymus, are more pronounced in
females (NTP, 1993b). In the process of studying and
comparing the metabolic and cellular basis of EGBE-
induced hemolysis, Ghanayem (1989) observed that
blood from female human volunteers showed a slightly
greater sensitivity to incubation with BAA than male
blood.
4.3.5. Age differences
It is recognized that childhood exposures can be im-
portant determinants of certain cancers (Anderson et
al., 2000), including early childhood bacterial infec-
tions (Rowland and Drumm, 1998). Because a bacte-
rial infection (Helicobacter hepaticus) has been associ-
ated with the development of liver hemangiosarcomas
in mice (Nyska et al., 1997), it is not unreasonable to
consider whether early childhood exposure to EGBE
might be more important than adult exposures towards
the formation of EGBE-induced liver hemangiosarco-
mas. However, it is generally recognized that children
have fewer risk factors for anemia than adults (Berliner
et al., 1995; Hord and Lukens, 1999), and Udden
(2002) has shown that the red blood cells of chil-
dren are no more sensitive to EGBE exposure than
adult red blood cells. Thus, if the proposed mode of
action for EGBE’s involvement in the formation of
these tumors in male mice is correct, there is no rea-
son to believe that human children would be a sus-
ceptible subpopulation due to the fact that a signif-
icant buildup of iron from hemolysis would not be
likely.
5. Summary
Since the publication of NTP’s draft report (NTP,
1998a,b) on their 2-year inhalation bioassay of ethy-
lene glycol butyl ether (EGBE; 2-butoxyethanol), there
has been considerable debate among scientists from
government, industry, and academia over EGBE’s hu-
man carcinogenic potential. In 1999, EPA concluded
that, while there was suggestive evidence from rodent
studies, forestomach tumors in female mice and liver
tumors in male mice, the human carcinogenicity of
EGBE could not be determined (U.S. EPA, 1999a).
Since that time, several research projects have been
completed which shed considerable light on the mech-
anisms for the formation of these tumors. When this
recently developed toxicological data for EGBE are
reviewed under current draft EPA assessment guide-
lines (U.S. EPA, 1999a), the evidence suggests that the
liver hemangiosarcomas in male mice and forestomach
tumors in female mice observed following EGBE expo-
sure developed via nonlinear modes of action and are of
questionable relevance to humans. However, some un-
certainty remains, particularly with respect to the spe-
cific mechanism of action for the formation of liver
tumors in mice. In making an assessment regarding the
relevance of liver hemangiosarcomas observed in mice
to humans, EPA must consider uncertainties related to
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the following:
- the amount of iron sequestered by liver endothelial
cells;
- the relative sensitivity of endothelial cells versus
other liver cells;
- the reasons for the apparent sensitivity of male over
female mice;
- the possibility of another mode of action (e.g., via
mutagenic metabolites).
Given that humans lack an organ which is histologi-
cally or functionally similar to the forestomach and are
insensitive to the hemolytic effects of EGBE, affirma-
tion of the nonlinear modes of action discussed in this
paper would almost certainly result in a determination
that humans would not be expected to be susceptible
to the forestomach and liver tumors observed in mice.
An external peer review panel has reviewed recently
completed toxicokinetic and genotoxicity research on
EGBE and its metabolite BAL9 to determine whether
the proposed nonlinear modes of action can be affirmed
at this time. Until the results of this peer review have
been assessed by the Agency, the existing IRIS deter-
mination (U.S. EPA, 1999a) that the human carcino-
genicity of EGBE “cannot be determined at this time”
applies.
Appendix A. Questions and Answers
Dr. Jeff Gift
Chair
Dr. Gift’s presentation is open for discussion. Ques-
tions?
Question from Floor
Why aren’t there endothelial sarcomas in other tis-
sues, why just the liver if it is going to act directly?
Dr. Gift
I think that is something that could stand additional
research as to why endothelial cells in the liver are
9 Technical comments submitted to EGBE Docket (OAR-2003-
0188) on 20 January 2004 by the American Chemistry Council in
response to EPA’s proposed rule to remove EGBE from the list of
Hazardous Air Pollutants (68 FR 65648, 21 November 2003).
sensitive relative to other cells. You do get haeman-
giosarcomas in the spleen for instance, perhaps by other
mechanisms. I think that perhaps there are protective
mechanisms in the spleen that are better than protective
mechanisms in the liver. I do not know for sure.
Chair
My recollection is that there were certainly haeman-
giosarcomas in other tissues, is that not right Rodney?
They just were not significantly increased? Other ques-
tions? No? Thank you
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